Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Description

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Conditions

Pancreatic Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Condition
Pancreatic Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Louisville

University of Louisville, Louisville, Kentucky, United States, 40202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥ 18 years if age
  • * Diagnosed with stage III pancreatic cancer
  • * Tumor is measurable
  • * Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2)
  • * Willing and able to comply with the protocol requirements
  • * Able to comprehend and have signed the informed consent to participate
  • * Participating in another clinical trial for the treatment of cancer at time of screening
  • * Are pregnant or currently breast feeding
  • * Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
  • * Have non-removable implants with metal parts within 1 cm of the target lesion
  • * Had a myocardial infarction within 3 months prior to enrollment

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Louisville,

Robert Martin, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Louisville

Study Record Dates

2026-04-01